What is Foldax?
Foldax is fundamentally transforming the landscape of heart valve replacement through the development of its TRIA heart valves. By moving away from traditional tissue-based valves, which often suffer from durability limitations, Foldax utilizes a proprietary biocompatible polymer that offers superior longevity and performance. The integration of robotic manufacturing processes ensures that each valve is produced with high precision, allowing for greater scalability and consistency in clinical outcomes. Currently, the company's TRIA Mitral Valves have achieved regulatory approval in India, while maintaining an investigational status in the United States. This dual-market strategy positions Foldax as a critical player in addressing the needs of diverse patient populations, including younger demographics and those suffering from rheumatic heart disease, who require more durable and accessible treatment options.
How much funding has Foldax raised?
Foldax has raised a total of $34M across 4 funding rounds:
Series A
$3.4M
Series B
$10.3M
Debt
$350K
Series D
$20M
Series A (2016): $3.4M, investors not publicly disclosed
Series B (2018): $10.3M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series D (2020): $20M featuring MemorialCare, Angel Physicians Fund, Kairos Ventures, Sayan Bioventures, Caltech, and BioStar Capital
Key Investors in Foldax
MemorialCare
A prominent hospital system based in Long Beach, California, that operates a network of primary hospitals and outpatient facilities, providing deep clinical expertise and strategic healthcare industry insights.
Kairos Ventures
A venture capital firm that focuses on supporting transformative technologies and companies that aim to improve human health and provide individuals with greater freedom and fulfillment.
Angel Physicians Fund
A specialized investment group comprised of medical professionals who provide both capital and clinical validation to early-stage and growth-stage healthcare innovations.
What's next for Foldax?
With the recent influx of capital, Foldax is well-positioned to accelerate its clinical trial programs and expand its manufacturing footprint. The strategic focus will likely center on securing further regulatory clearances in key international markets and preparing for potential FDA milestones in the United States. As the company scales its robotic manufacturing capabilities, it aims to reduce the cost of production while maintaining the high-quality standards required for life-critical cardiovascular implants. Investors are closely monitoring the company's ability to translate its technological advantages into widespread clinical adoption, which remains the primary catalyst for long-term value creation in the medical device industry.
See full Foldax company page
